Skip to main content

Third Wave CEO Bought 5,000 Shares After Stock Fell

NEW YORK, March 17 (GenomeWeb News) - John Puisis, CEO of Third Wave Technologies, purchased 5,000 of his company's shares on March 15 at the low point of a stock-price slide precipitated by disappointing fourth quarter earnings, GenomeWeb News has learned.


Third Wave's share price reached $4.53 when Puisis made the recent purchase. John Nies, a Third Wave director, purchased 5,000 shares on March 11 at $4.77. The shares, which have more than regained the ground they lost since the decline, were up 5.34 percent, or $.26, at $5.11 in late-afternoon trading today. However, they are still short of the stock's 52-week high of $9.08.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.